Posology: Individuals 16 years of age and older: COMIRNATY is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each) at least 21 days apart (see Pharmacology: Pharmacodynamics under Actions; Precautions).
There are no data available on the interchangeability of COMIRNATY with other COVID-19 vaccines to complete the vaccination course. Individuals who have received 1 dose of COMIRNATY should receive a second dose of COMIRNATY to complete the vaccination course.
Paediatric population: The safety and efficacy of COMIRNATY in children and adolescents aged less than 16 years of age have not yet been established. Limited data are available.
Elderly population: No dosage adjustment is required in elderly individuals ≥65 years of age.
Method of administration: COMIRNATY should be administered intramuscularly.
The preferred site is the deltoid muscle of the upper arm.
Do not inject the vaccine intravascularly, subcutaneously or intradermally.
The vaccine should not be mixed in the same syringe with any other vaccines or medicinal products.
For precautions to be taken before administering the vaccine, see Precautions.
For instructions regarding thawing, handling and disposal of the vaccine, see Special precautions for disposal and other handling under Cautions for Usage.